The Effect of Liraglutide on the GIT

NCT04008290 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide affects stomach and intestinal movement in adults with obesity.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, double-blind prevention study

Participants 15 people Planned (estimated).

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2020-04 · est. completion 2021-04

What this study is testing ClinicalTrials.gov NCT04008290 ↗

Description as written by the study sponsor.

Liraglutide is a glucose-like peptide 1 agonist, currently used as an effective weight-loss treatment. Its mechanism of action has not yet been elucidated. We want to investigate whether liraglutide affects MMC activity, gastrointestinal hormone release, glucose whole blood levels, hunger ratings and ad libitum food intake in healthy volunteers.

Treatments tested

0.6 mg Liraglutide also known as Victoza Drug

For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of 0.6 mg liraglutide. The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.
Placebo also known as saline solution Drug

For a duration of 5 consecutive days, subjects will receive a subcutaneous injection in the abdomen of placebo (0.9% saline solution). The injection will be placed by a trained nurse at 8 o'clock every morning. A wash out period of at least one week will be respected between the two treatment weeks.

Main thing measured	MMC activity compared between placebo and treatment with liraglutide
Sponsor	Universitaire Ziekenhuizen KU Leuven
Conditions studied	Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04008290 ↗